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ABSTRACT
Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) is a common chemotherapy side effect, but its preven-
tion and treatment remains a challenge. Neurotoxicity may lead to dose limitation or even treatment discontinuation, 
and therefore potentially affect the efficacy of anticancer treatment and long term outcomes. The practice to administer 
gabapentin for neuropathy may be applicable, but is limited by insufficient studies. The aim of our study was to assess the 
presence of chemotherapy-induced peripheral neuropathy in ovarian cancer patients treated with first-line paclitaxel and 
carboplatin chemotherapy and evaluate the effectiveness of gabapentin in treatment of this condition.
Material and methods: 61 ovarian cancer patients treated with first line chemotherapy were included in the study. The 
first phase of the study was to assess neurological condition of each patient by: neuropathy symptoms scale, McGill’s 
scale, neurological deficit and quality of life, during the chemotherapy. In the second phase of the study we evaluated the 
response to gabapentin treatment in a group of patients who developed neuropathy. 
Results: 78.7% of the patients developed chemotherapy related neuropathy. During the course of chemotherapy these pa-
tients experienced significant exacerbation of neuropathy symptoms (p < 0.0001), neuropathic pain (p < 0.0001), neurologic 
deficit (p < 0.0012) and worsening of quality of life (p < 0.0002). Patients who were qualified to undergo the gabapentin 
treatment observed improvement in symptoms (p < 0.027), pain (p < 0.027) and neurologic deficit (p < 0.019). Quality of 
life did not change significantly after gabapentin treatment (p < 0.128).
Conclusions: Chemotherapy substantially deteriorates the neurologic condition of the patients and the quality of life. Paclitaxel 
and carboplatin treated patients may benefit from gabapentin therapy in chemotherapy-induced peripheral neuropathy. 
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INTRODUCTION
Chemotherapy-induced peripheral neuropathy (CIPN) 
is a common toxicity which occurs in about 70–90% of pa-
tients treated with chemotherapy. It affects nerve function 
resulting in peripheral, bilateral glove and stocking paraes-
thesias, such as numbness, burning, tingling sensations, 
pain, muscle weakness and cramps. Loss of temperature 
sensibility may also be experienced. It is caused by sensory, 
rather than motor, axonal damage [1]. Most often, this type 
of toxicity is associated with the use of platinum agents, tax-
anes and vinka alkaloids. Usually the symptoms get worse 
as the chemotherapy is continued, but may partially or 
completely resolve after treatment cessation [2]. In a subset 
of patients the symptoms have been reported as irreversible 
despite the time that passed since the administration of last 
dose of chemotherapy [3]. 
Neurotoxicity induced by cytotoxic agents can ad-
versely affect treatment and long-term outcomes leading to 
dose-limitation or even treatment discontinuation. Recently, 
more impact is put on effective support of cancer patients 
during and after chemotherapy due to increasing number 
of cancer treatment survivors and longer post treatment 
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survival time. Unfortunately, neuropathy prevention and 
treatment still remain a big challenge. According to the 
latest ASCO Guidelines there are no established agents 
recommended for the CIPN prevention and serotonin- nor-
epinephrine reuptake inhibitor (SNRI) duloxetine is the only 
drug proven to be effective and recommended in the treat-
ment of CIPN [4]. The clinical practice to offer anticonvul-
sants (gabapentin), antidepressants (tricyclics) and topical 
capsaicin or lidocaine may be applicable, but is limited by 
lack of conclusive studies on CIPN treatment.
Gabapentin is an anti-epileptic drug, registered for the 
treatment of post-herpetic neuralgia, diabetic neuropathy, 
spinal cord injury pain [5] and neuropathic cancer pain [6]. Its 
analgesic mechanism is probably due to antagonism of the 
α2δ calcium channels at presynaptic sites [7]. The most com-
mon side-effects are nausea, vertigo, somnolence, weight 
gain and asthenia. These can lead to dosage adjustment 
and partial reduction in neuropathic pain.
The purpose of this study was to assess the incidence 
of chemotherapy-induced peripheral neuropathy in ovar-
ian cancer patients treated with first-line adjuvant paclitaxel 
and carboplatin chemotherapy and to evaluate the effective-
ness of gabapentin in treatment of neuropathy symptoms.
MATERIAL AND METHODS 
Data analysis was performed prospectively, on patients 
admitted to Department of Obstetrics and Gynecology due 
to ovarian cancer. Our study included 61 women, aged 47–
–63. All of the patients were diagnosed with ovarian cancer 
FIGO stage III A–C and underwent initial surgical treatment- 
radical hysterectomy, bilateral salpingooophorectomy and 
omentectomy according to ovarian cancer surgical treat-
ment protocol. All of the participants were later treated with 
first line paclitaxel and carboplatin chemotherapy, receiving 
standard doses of paclitaxel (175/m2) and carboplatin (ac-
cording to AUC 6, but not more than 400 mg/m2). Patients 
underwent 6 courses of chemotherapy, every 3 weeks. The 
study was approved by the Institutional Review Board. The 
exclusion criteria was diabetes mellitus and any other po-
tential cause for neuropathy prior to chemotherapy, such 
as neurologic or rheumatic diseases. 
Neurological examination was performed every 3 weeks 
— during each hospital admission for chemotherapy. Pa-
tients were assessed according to scales that are commonly 
used for evaluation of neuropathy symptoms such as neu-
ropathy symptoms scale (Tab. 1) and McGill’s scale (Tab. 2). 
All patients underwent clinical neurological examination 
consisted of Achilles tendon reflex, touch sensibility (by 
means of standarized Semmes-Weinstein 5.07/10 g/cm2 mo-
nofilament), pain sensitivity and cryaesthesia (Tab. 3). The 
examination was performed by qualified study team mem-
bers, all of whom were medical doctors, trained to perform 
neurological examination. The participants were asked to 
fill the quality of life questionnaire during each stay, using 
a 10-points visual analogue scale (VAS) to determine their 
Table 1. Neuropathy symptoms scale
Lower limbs Present Absent
Burning sensations 2 0
Numbness 2 0
Paraesthesia 2 0
Cramps 1 0
Pain 1 0
Muscle weakness 1 0
Symptoms localization
Foot 2
Shin 1
Other 0
Symptoms intensification
Night 2
Day and night 1
During sleep 1
Day 0
Symptoms improvement
During walk 2
During standing 1
During sitting or laying 0
Table 2. McGill’s neuropathic pain scale
Lack of pain  0
Low intensification pain  1 2 3 4 5 6
Medium intensification pain  7 8 9 10 11 12 13 14
Hard intensification pain  15 16 17 18 19 20
Table 3. Neurologic deficit scale
Achilles tendon reflex Points
Within norm 0
Can be developed 1 point/side
Cannot be developed 2 points/sides
Cryaesthesia
Within norm 0
Lowered/absent 1 point/side
Touch sensibility
Within norm 0
Lowered/absent 1 point/side
Pain sensitivity
Within norm 0
Lowered/absent 1 point/side
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comfort of life, where 1 was very bad and 10 was very good. 
Each patient who developed neuropathy symptoms du-
ring the course of chemotherapy was offered gabapentin 
300 mg, 3 times daily. The patients were offered maximum 
dose of 900 mg per day. The minimal effective dose was 
approved and recommended by our consultant neurologist 
to minimize the possible side effects of the treatment and 
therefore avoid treatment discontinuation. Final neurologic 
examination was performed after a month of treatment 
with gabapentin. If the drug tolerance was good and the 
patients reported improvement of neuropathy symptoms, 
the gabapentin treatment was continued until the end of 
cytotoxic therapy in the same dose.
Statistical analysis
Wilcoxon test was used to compare baseline and final 
outcomes of the above mentioned scales and examina-
tions. The significance level was p < 0.05. All analyses were 
performed using PQstat 1.4.8. 
RESULTS
In the study group of 61 patients, 48 (78.7%) developed 
symptoms of neuropathy. The typical „gloves and socks” 
signs affected 24 (39%) women, 20 (32.8%) — only feet 
and 4 (8.2%) — only hands. In a first phase of the study we 
assessed if our patients experienced significant worsening 
of the neuropathic symptoms during the chemotherapy 
treatment. Statistical analysis of the first phase included 
the time before introduction of any additional neuropathy 
treatment. In most patients, severe exacerbation of the 
neuropathic symptoms, neuropathic pain (McGill’s scale) 
and neurologic deficit were observed after the third cycle 
of chemotherapy. These findings were also covered by the 
results of neurological examination. The deterioration of 
the neuropathic symptoms resulted also in the significantly 
worsening of quality of life (Tab. 4, Fig. 1). 
In the second phase of the study we wanted to evalu-
ate the effectiveness of gabapentin pharmacotherapy in 
chemotherapy related neuropathy. In the group of patients 
(20 women), who were qualified for gabapentin treatment, 
basing on significant worsening of neuropathy symptoms 
reported by patients or shown in the neurological exami-
nation, we performed the neurologic examination and 
tests before gabapentin administration (at baseline visit). 
The final neurologic assessment was done after a month 
of gabapentin treatment. Significant improvement of neu-
ropathy symptoms, neurologic deficit and reduction of 
neuropathic pain was observed during the final examina-
tion. However, there was no significant change in quality 
of life in the study group (Tab. 5, Fig. 2). It is important to 
mention that 7 patients were withdrawn from the study 
group due to adverse effects of gabapentin. Despite that, 
they were all included into the study statistical analysis. The 
Table 4. Assessment of neuropathy after chemotherapy, without 
gabapentin pharmacotherapy
Type of the scale p
Neuropathy symptoms 0.0001
McGill’s 0.0001
Neurologic deficit 0.0012
Quality of life 0.0002
16
14
12
10
8
6
4
2
0
Neuropathy
symptoms I
Neuropathy
symptoms II
20
15
10
5
0
McGill’s
scale I
McGill’s
scale II
6
5
4
3
2
1
0
Neurologic
decit I
Neurologic
decit II
10
8
6
4
2
0
Quality
of life I
Quality
of life II
A B C D
Mediana
Q1.Q3
Min/Max
Table 5. Effectiveness of gabapentin pharmacotherapy, comparison 
between baseline visit and visit after gabapentin therapy
Type of the scale p
Neuropathy symptoms 0.027
McGill’s 0.027
Neurologic deficit 0.019
Quality of life 0.128
Figure 1. Comparison of visit I (when neuropathy starts) and visit II (without gabapentin treatment) 
A — neuropathy symptoms, B — McGill’s scale, C — neurologic deficit, D — quality of life
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main complaint was on vertigo and side effects from the 
gastrointestinal tract. 
DISCUSSION
Chemotherapy-induced peripheral neuropathy is 
a common adverse effect which affects long-term quality 
of life and may potentially influence long-term outcomes 
of anti-cancer treatment. The overall incidence depends on 
the type and dose of cytostatic drug and the duration of 
the treatment. Any other patient’s dependent risk factors 
are not known. The incidence of CIPN according to our 
study — 78.8% is consistent with another surveys [8, 9]. 
The importance of the problem should not be underesti-
mated, because the neuropathy symptoms may not only 
persist for up to 12 years and seriously affect quality of life 
[8], but also influence the long term treatment outcomes 
causing chemotherapy dose reductions. Patients expect 
effective cancer treatment, as well as the side effect re-
ducing supportive therapy. Gabapentin is a drug which 
has been studied in a treatment of diabetic neuropathy 
and post herpetic neuralgia. The 2013 Cochrane Database 
overview of 29 studies on over 3000 patients, provided 
some evidence of gabapentin efficacy. This drug reduced 
the neuropathic pain by half, in 10–25% of the patients, 
without any improvement in the remaining group of pa-
tients. About 25% of patients had to stop taking the drug, 
because of bad tolerance [9].
We also observed side effects of gabapentin, which 
contributed to therapy cessation in 35% of patients. Our 
research of Cochrane database did not reveal any reviews 
on the use of gabapentin in chemotherapy induced neuro-
pathy. The only reliable recommendations for prevention 
and management of CIPN were published by ASCO. These 
Guidelines comprise 48 randomized controlled trials. Ac-
cording to that analysis none of the following drugs and 
supplements should be recommended for CIPN preven-
tion: acetyl-L-carnitine, amitriptyline, Ca, Mg, glutathione, 
nimodipine, retinoic acid and vitamin E, due to the lack of 
conclusive studies supporting their use in CIPN prophylaxis. 
Selective serotonin and norepinephrine reuptake inhibi-
tor (SNRI) duloxetine is the only drug proven to be effective 
in CIPN treatment. Although the data available for gabapen-
tin is limited, the panel of specialists found it reasonable to 
try this drug, because of unmet need for CIPN treatment and 
the relative safety of the therapy [10]. There was only one 
negative randomized trial on 115 patients, which compared 
gabapentin in dose 2700 mg for 6 weeks with placebo. This 
study showed no benefit from using gabapentin in CIPN 
treatment [11]. The major limitation of this study appeared 
to be the heterogeneous group of patients, treated with 
different chemotherapeutics (paclitaxel, docetaxel, carbo-
platin, cisplatin, oxaliplatin, vincristine and vinblastine). As 
the exact pathophysiology of CIPN is not explained, it is 
suggested that each cytostatic agent has a different me-
chanism of nerve damage [12]. It is hypothesized that the 
treatment should also be specific for each chemotherapeu-
tic agent [13]. Our study group was much more balanced 
as it involved only women treated for ovarian cancer with 
standard doses of paclitaxel (175 mg/m2) and carboplatin 
(acc. AUC 6). On the other hand, the important limitation of 
our analysis was a relatively small study group. However, we 
obtained significant outcomes concerning the improvement 
in neurological examination, neuropathic symptoms and 
neuropathic pain, the quality of life remained on the same le-
vel. The lack of quality of life improvement can be explained 
by relatively large amount of side-effects of gabapentin. 
This is even more surprising according to the fact that in our 
study the maximum administered dose of gabapentin was 
900 mg per day, which is much lower comparing to other 
studies involving gabapentin. 
Figure 2. Comparison of visit I (without gabapentin) and visit II (after a month of gabapentin pharmacotherapy) 
A — neuropathy symptoms, B — McGill’s scale, C — neurologic deficit, D — quality of life
16
14
12
10
8
6
4
2 
Neuropathy
symptoms I
Neuropathy
symptoms II
Mediana
Q1.Q3
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18
16
14
12
10
8
6
4
2
McGill’s
scale I
McGill’s
scale II
6
5
4
3
2
1
0
Neurologic
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Neurologic
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9
8
7
6
5
4
Quality
of life I
Quality
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CONCLUSIONS
Chemotherapy substantially deteriorates the neurologic 
condition of the patients and the quality of life. Paclitaxel and 
carboplatin treated patients may benefit from gabapentin 
therapy in chemotherapy-induced peripheral neuropathy. 
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